Document Detail


Immunogenicity negatively influences the outcome of adalimumab treatment in Crohn's disease.
MedLine Citation:
PMID:  18691349     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Adalimumab is an effective treatment in patients with Crohn's disease; as it is a humanized anti-tumour necrosis factor monoclonal antibody, immunogenicity is thought not to be of any significance.
AIM: To assess whether antibodies to adalimumab (ATAs) affect adalimumab treatment outcome in patients with Crohn's disease previously treated with infliximab.
METHODS: A retrospective study was performed. Patients with active Crohn's disease and who had lost response or were intolerant to infliximab were treated with adalimumab. Clinical response and side effects were assessed as were serum ATAs and antibodies to infliximab (ATIs).
RESULTS: In total 30 patients [M/F (7/23)], median age 36 years (range 21-73) were treated with adalimumab for 318 days (median range 83-632). Clinical response was 77% (23/30), a dose escalation was necessary in eight (27%) patients and side effects were observed in 47% (14/30). In five patients (17%) ATAs were detected; of these patients, four were nonresponders. The presence of ATAs was related to nonresponse to adalimumab (P = 0.006). ATIs were positive in 57% of patients (17/30) and serum levels were significantly increased in adalimumab nonresponders (P = 0.01).
CONCLUSION: Immunogenicity plays a role in adalimumab treatment because of the development of ATAs.
Authors:
R L West; Z Zelinkova; G J Wolbink; E J Kuipers; P C F Stokkers; C J van der Woude
Related Documents :
7209379 - Sclerosing cholangitis in ulcerative colitis.
11355319 - Adenocarcinoma in the ileal pouch: late risk of cancer after restorative proctocolectomy.
22386699 - Acute effect of sildenafil on central hemodynamics in mechanically ventilated patients ...
9870799 - Inflammatory bowel disease in saudi arabia: presentation and initial management.
7847289 - Paradoxical response to heparin in 10 patients with ulcerative colitis.
17903939 - Cerebral venous sinus thrombosis in a patient with ulcerative colitis.
6160519 - Preliminary studies with an implantable multimodal a-v pacemaker for reciprocating atri...
3789619 - Aetiological factors and management of priapism in bristol 1978-1983.
19662469 - Deep venous thrombosis in patients with acute cervical spinal cord injury in a japanese...
Publication Detail:
Type:  Journal Article     Date:  2008-08-08
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  28     ISSN:  1365-2036     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-10-30     Completed Date:  2009-02-20     Revised Date:  2013-05-27    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  England    
Other Details:
Languages:  eng     Pagination:  1122-6     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. r.west@erasmusmc.nl
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Anti-Inflammatory Agents / administration & dosage*,  immunology
Antibodies, Monoclonal / administration & dosage*,  immunology
Antibodies, Monoclonal, Humanized
Crohn Disease / drug therapy*,  immunology
Dose-Response Relationship, Drug
Female
Humans
Male
Middle Aged
Retrospective Studies
Treatment Outcome
Tumor Necrosis Factor-alpha / administration & dosage*,  immunology
Young Adult
Chemical
Reg. No./Substance:
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/Antibodies, Monoclonal, Humanized; 0/Tumor Necrosis Factor-alpha; 0/infliximab; FYS6T7F842/adalimumab

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Relative torque contribution of vastus medialis muscle at different knee angles.
Next Document:  Hepatitis vaccination in patients with hepatitis C: practice and validation of codes at a large Vete...